Spontaneous Bilateral Femoral Fractures After High-Dose Zoledronic Acid.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Orthopedics

• Publication date

  2015-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.3928/01477447-20151020-16PMID 26558671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study

  2014cited by this paper
• Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures

  2014cited by this paper
• Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy.

  2014cited by this paper
• Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy.

  2013cited by this paper
• Case of femoral diaphyseal stress fracture after long-term risedronate administration diagnosed by iliac bone biopsy

  2013cited by this paper
• Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma

  2012cited by this paper
• A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid

  2011cited by this paper
• Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?

  2011cited by this paper
• Bisphosphonate use and atypical fractures of the femoral shaft.

  2011cited by this paper
• Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma

  2010cited by this paper
• Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men

  2010cited by this paper
• Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.

  2010cited by this paper
• Alendronate-related femoral diaphysis fracture—what should be done to predict and prevent subsequent fracture of the contralateral side?

  2010cited by this paper
• Unusual mid‐shaft fractures during long‐term bisphosphonate therapy

  2010cited by this paper
• Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow

  2008cited by this paper
• Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases

  2008cited by this paper
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Biological enhancement of tibial diaphyseal aseptic non-unions: the efficacy of autologous bone grafting, BMPs and reaming by-products.

  2007cited by this paper
• Suppressed Bone Turnover by Long‐Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib

  2004cited by this paper
• Modern Therapy for Paget’s Disease of Bone

  2002cited by this paper

• No citing papers are available for this paper.